Atrophic lichen planus

Atrophic lichen planus is a rare clinical variant of lichen planus, a chronic inflammatory disorder that primarily affects the skin. In this subtype, the characteristic violaceous (purple-colored) papules and plaques of lichen planus are accompanied by atrophy, meaning thinning and wasting of the affected skin. The lesions typically appear as well-demarcated, slightly depressed patches with a whitish or violaceous hue, often surrounded by a hyperpigmented border. The skin becomes thin and fragile in affected areas. Atrophic lichen planus most commonly involves the lower extremities, trunk, and occasionally the scalp, where it may lead to scarring alopecia (permanent hair loss). It is classified under the broader category of lichen planus (ICD-10: L43.8, other lichen planus). The exact cause of atrophic lichen planus, like other forms of lichen planus, is not fully understood but is believed to involve a T-cell-mediated autoimmune response directed against basal keratinocytes in the skin. The condition may be associated with other autoimmune disorders, hepatitis C virus infection, and certain medications. Patients may experience mild itching or discomfort, though some lesions can be asymptomatic. The atrophic changes distinguish this variant from classic lichen planus and may sometimes be confused with other atrophic skin conditions such as morphea or lichen sclerosus. Treatment of atrophic lichen planus is similar to that of other lichen planus variants and is primarily aimed at reducing inflammation and managing symptoms. First-line therapy typically includes potent topical corticosteroids. For more widespread or refractory disease, options may include topical calcineurin inhibitors (such as tacrolimus), phototherapy (narrowband UVB or PUVA), or systemic immunosuppressive agents such as oral corticosteroids, methotrexate, or acitretin. The condition may follow a chronic relapsing course, and the atrophic changes can be permanent even after the inflammatory component resolves. Regular follow-up is recommended to monitor for complications and disease progression.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Atrophic lichen planus